SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinoma

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Li, Pu ^a,b   Lin, Ying ^a   Zhang, Yu ^c   Zhu, Zhenggang ^b   Huo, Keke ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapeutic resistance; Hepatocellular carcinoma; Metastasis; SSX2IP

Indexed keywords

CISPLATIN; FLUOROURACIL; LEUKEMIA ANTIGEN; SYNOVIAL SARCOMA X BREAKPOINT 2 INTERACTING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CANCER RESISTANCE; CANCER SIZE; CANCER SURVIVAL; CARCINOGENESIS; CHEMOSENSITIVITY; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PERITONEUM METASTASIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL TIME; TUMOR THROMBUS; UPREGULATION; WOUND HEALING;

CARRIER PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM METASTASIS;

EID: 84874398620     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-52     Document Type: Article

References (28)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47. 10.3322/canjclin.52.1.23, 11814064.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
3. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 2007, 35:D26-D31. 10.1093/nar/gkl993, 1761442, 17148475.
4. Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML. DNA copy number losses in human neoplasms. Am J Pathol 1999, 155:683-694. 10.1016/S0002-9440(10)65166-8, 1866903, 10487825.
5. Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998, 152:1107-1123. 1858578, 9588877.
6. Cigudosa JC, Parsa NZ, Louie DC, Filippa DA, Jhanwar SC, Johansson B, Mitelman F, Chaganti RS. Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chromosomes Cancer 1999, 25:123-133. 10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.0.CO;2-4, 10337996.
7. Crew AJ, Clark J, Fisher C, Gill S, Grimer R, Chand A, Shipley J, Gusterson BA, Cooper CS. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 1995, 14:2333-2340. 398342, 7539744.
8. de Bruijn DR, dos Santos NR, Kater-Baats E, Thijssen J, van den Berk L, Stap J, Balemans M, Schepens M, Merkx G, van Kessel AG. The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP. Genes Chromosomes Cancer 2002, 34:285-298. 10.1002/gcc.10073, 12007189.
9. Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S, Wells JW, Banham AH, Mufti GJ. Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005, 335:1293-1304. 10.1016/j.bbrc.2005.08.024, 16112646.
10. Denniss FA, Breslin A, Ingram W, Hardwick NR, Mufti GJ, Guinn BA. The leukaemia-associated antigen, SSX2IP, is expressed during mitosis on the surface of myeloid leukaemia cells. Br J Haematol 2007, 138:668-669. 10.1111/j.1365-2141.2007.06706.x, 17686061.
11. Breslin A, Denniss FA, Guinn BA. SSX2IP: an emerging role in cancer. Biochem Biophys Res Commun 2007, 363:462-465. 10.1016/j.bbrc.2007.09.052, 17904521.
12. Guinn BA, Bullinger L, Thomas NS, Mills KI, Greiner J. SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. Br J Haematol 2008, 140:250-251.
13. Guinn B, Greiner J, Schmitt M, Mills KI. Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements. Blood 2009, 113:1203-1204.
14. Zhang L, Greiner J. Leukemia-associated antigens are immunogenic and have prognostic value in acute myeloid leukemia. Immunotherapy 2011, 3:697-699. 10.2217/imt.11.50, 21668302.
15. Asada M, Irie K, Morimoto K, Yamada A, Ikeda W, Takeuchi M, Takai Y. ADIP, a novel Afadin- and alpha-actinin-binding protein localized at cell-cell adherens junctions. J Biol Chem 2003, 278:4103-4111. 10.1074/jbc.M209832200, 12446711.
16. Fukumoto Y, Kurita S, Takai Y, Ogita H. Role of scaffold protein afadin dilute domain-interacting protein (ADIP) in platelet-derived growth factor-induced cell movement by activating Rac protein through Vav2 protein. J Biol Chem 2011, 286:43537-43548. 10.1074/jbc.M111.308858, 3234878, 22027834.
17. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003, 5:711-719. 10.1038/ncb1019, 12844144.
18. Buccione R, Caldieri G, Ayala I. Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer Metastasis Rev 2009, 28:137-149. 10.1007/s10555-008-9176-1, 19153671.
19. Chen J, Han Q, Pei D. EMT and MET as paradigms for cell fate switching. J Mol Cell Biol 2012, 4:66-69. 10.1093/jmcb/mjr045, 22140271.
20. Vincan E, Barker N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis 2008, 25:657-663. 10.1007/s10585-008-9156-4, 18350253.
21. Thompson EW, Williams ED. EMT and MET in carcinoma-clinical observations, regulatory pathways and new models. Clin Exp Metastasis 2008, 25:591-592. 10.1007/s10585-008-9189-8, 18566898.
22. Aspenstrom P, Ruusala A, Pacholsky D. Taking Rho GTPases to the next level: the cellular functions of atypical Rho GTPases. Exp Cell Res 2007, 313:3673-3679. 10.1016/j.yexcr.2007.07.022, 17850788.
23. Mula RV, Bhatia V, Falzon M. PTHrP promotes colon cancer cell migration and invasion in an integrin alpha6beta4-dependent manner through activation of Rac1. Cancer Lett 2010, 298:119-127. 10.1016/j.canlet.2010.06.009, 2946490, 20637541.
24. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004, 40:1474-1484. 10.1016/j.ejca.2004.02.027, 15196530.
25. Whang-Peng J, Cheng A-L, Hsu C, Chen C-M. Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. Journal of Experimental & Clinical Medicine 2010, 2:93-103. 10.1016/S1878-3317(10)60016-2, 23487751.
26. Asada M, Irie K, Yamada A, Takai Y. Afadin- and alpha-actinin-binding protein ADIP directly binds beta'-COP, a subunit of the coatomer complex. Biochem Biophys Res Commun 2004, 321:350-354. 10.1016/j.bbrc.2004.06.143, 15358183.
27. Mo W, Zhang JT. Human ABCG2: structure, function, and its role in multidrug resistance. International journal of biochemistry and molecular biology 2012, 3:1-27. 3325772, 22509477.
28. Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 2002, 1:427-434. 10.4161/cbt.1.4.25, 12477055.